# Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

> **NCT05951023** · PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 42 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Eszopiclone 2 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05951023
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-31
- **Primary completion:** 2025-07-23
- **Final completion:** 2025-10-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05951023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05951023, "Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05951023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*